ZA200805261B - EphA2 bite molecules and uses thereof - Google Patents

EphA2 bite molecules and uses thereof

Info

Publication number
ZA200805261B
ZA200805261B ZA200805261A ZA200805261A ZA200805261B ZA 200805261 B ZA200805261 B ZA 200805261B ZA 200805261 A ZA200805261 A ZA 200805261A ZA 200805261 A ZA200805261 A ZA 200805261A ZA 200805261 B ZA200805261 B ZA 200805261B
Authority
ZA
South Africa
Prior art keywords
bite molecules
epha2 bite
epha2
molecules
bite
Prior art date
Application number
ZA200805261A
Inventor
Lutterbuese Petra
Lutterbuese Ralf
Peter A Kiener
Baeurele Patrick
Michael S Kinch
Roff Shannon
Kufer Peter
Bruckheimer Elizabeth
Schlereth Bernd
Scott A Hammond
Original Assignee
Micromet Ag
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet Ag, Medimmune Llc filed Critical Micromet Ag
Publication of ZA200805261B publication Critical patent/ZA200805261B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA200805261A 2005-12-21 2008-06-18 EphA2 bite molecules and uses thereof ZA200805261B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75336805P 2005-12-21 2005-12-21

Publications (1)

Publication Number Publication Date
ZA200805261B true ZA200805261B (en) 2009-08-26

Family

ID=38189130

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200805261A ZA200805261B (en) 2005-12-21 2008-06-18 EphA2 bite molecules and uses thereof

Country Status (12)

Country Link
US (1) US20080044413A1 (en)
EP (1) EP1981532A4 (en)
JP (1) JP2009521474A (en)
KR (1) KR20080090441A (en)
CN (1) CN101426521A (en)
AU (1) AU2006327175A1 (en)
CA (1) CA2633713A1 (en)
IL (1) IL192279A0 (en)
MX (1) MX2008008046A (en)
RU (1) RU2008129827A (en)
WO (1) WO2007073499A2 (en)
ZA (1) ZA200805261B (en)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2199390T (en) 2007-08-30 2017-03-15 Daiichi Sankyo Co Ltd Anti-epha2 antibody
US9308257B2 (en) 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
WO2009120922A2 (en) 2008-03-27 2009-10-01 Zymogenetics, Inc. Compositions and methods for inhibiting pdgfrbeta and vegf-a
GB0908613D0 (en) * 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
WO2011003071A1 (en) * 2009-07-02 2011-01-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods of modulating hepatitis c virus infection
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2498797A4 (en) * 2009-11-09 2013-12-25 Brigham & Womens Hospital Treatment of heart disease
WO2011057249A2 (en) 2009-11-09 2011-05-12 The Brigham And Women's Hospital, Inc. Treatment of heart disease
JP5808349B2 (en) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー Biomarkers for theranosis
KR20130043104A (en) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 Circulating biomarkers for disease
CN106432495A (en) * 2010-07-22 2017-02-22 加利福尼亚大学董事会 Anti-tumor antigen antibodies and methods of use
JP5953303B2 (en) 2010-07-29 2016-07-20 ゼンコア インコーポレイテッド Antibodies with modified isoelectric points
WO2012066058A1 (en) 2010-11-16 2012-05-24 Boehringer Ingelheim International Gmbh Agents and methods for treating diseases that correlate with bcma expression
WO2013026837A1 (en) * 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
AU2012298535A1 (en) * 2011-08-23 2014-02-06 Roche Glycart Ag Bispecific antigen binding molecules
PT2748201T (en) * 2011-08-23 2018-02-08 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
US11098115B2 (en) * 2011-09-29 2021-08-24 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
WO2013105856A1 (en) 2012-01-13 2013-07-18 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
EP2820047B1 (en) * 2012-03-01 2018-04-25 Amgen Research (Munich) GmbH Long life polypeptide binding molecules
CA2874864C (en) * 2012-08-14 2023-02-21 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
CA3211863A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP2964675B1 (en) * 2013-03-05 2018-06-20 Baylor College Of Medicine Engager cells for immunotherapy
CA2903096A1 (en) * 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus
US10544187B2 (en) 2013-03-15 2020-01-28 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
ES2742224T3 (en) * 2013-11-07 2020-02-13 Memorial Sloan Kettering Cancer Center Bispecific anti-WT1 / HLA antibodies
CA2945486A1 (en) 2014-02-07 2015-08-13 Mcmaster University Trifunctional t cell-antigen coupler and methods and uses thereof
PL3122781T3 (en) 2014-03-28 2020-06-15 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
KR20230155600A (en) 2014-04-03 2023-11-10 아이쥐엠 바이오사이언스 인코포레이티드 Modified j-chain
AU2015279316B2 (en) 2014-06-27 2021-03-04 Innate Pharma Multispecific NKp46 binding proteins
AU2015279321B2 (en) 2014-06-27 2021-03-04 Innate Pharma, S.A. Multispecific antigen binding proteins
US10501553B2 (en) * 2014-11-19 2019-12-10 Memorial Sloan-Kettering Cancer Center Methods and compositions for cancer treating conditions relating to over expressions of EphA2
MY184268A (en) 2014-11-26 2021-03-30 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CA2968878A1 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
MA41433A (en) * 2015-01-26 2017-12-05 Baylor College Medicine UNIVERSAL IMMUNE CELLS FOR ANTI-CANCER IMMUNOTHERAPY
SG11201705988UA (en) 2015-02-24 2017-08-30 Bioatla Llc Conditionally active biological proteins
IL297997A (en) 2015-03-04 2023-01-01 Igm Biosciences Inc Cd20 binding molecules and uses thereof
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
CA2990518A1 (en) 2015-06-23 2016-12-29 Innate Pharma Multispecific nk engager proteins
MX2018001568A (en) 2015-08-07 2019-04-25 Seattle Children´S Hospital Dba Seattle Children´S Res Institute Bispecific car t-cells for solid tumor targeting.
ES2819870T3 (en) * 2015-09-30 2021-04-19 Igm Biosciences Inc Modified J-chain binding molecules
JP7065766B2 (en) 2015-09-30 2022-05-12 アイジーエム バイオサイエンシズ インコーポレイテッド Bonded molecule with modified J chain
ES2873846T3 (en) 2015-11-19 2021-11-04 Revitope Ltd Functional Antibody Fragment Complementation for a Two-Component System for Targeted Elimination of Unwanted Cells
EP3387013B1 (en) 2015-12-07 2022-06-08 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
US11534466B2 (en) 2016-03-09 2022-12-27 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
CN109952319B (en) 2016-06-02 2023-08-25 英美偌科有限公司 Quantitative dosing regimen for gp100 specific TCR-anti-CD 3 scFv fusion proteins
RU2022104399A (en) 2016-06-14 2022-05-05 Ксенкор, Инк. BISPECIFIC ANTIBODIES-CHECKPOINT INHIBITORS
RU2019102008A (en) 2016-06-28 2020-07-28 Ксенкор, Инк. HETERODIMERIC ANTIBODIES THAT BIND TYPE 2 SOMATOSTATIN RECEPTOR
WO2018006005A1 (en) 2016-06-30 2018-01-04 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
BR112019007288A2 (en) 2016-10-14 2019-07-09 Xencor Inc bispecific heterodimeric protein, nucleic acid and expression vector compositions, expression vector, host cell, and methods for producing bispecific heterodimeric protein and for treating cancer in a patient
US11408005B2 (en) 2016-12-12 2022-08-09 Seattle Children's Hospital Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
AU2018269370A1 (en) 2017-05-16 2019-12-05 The Johns Hopkins University Manabodies and methods of using
US20200116700A1 (en) * 2017-06-30 2020-04-16 Osaka University Method for predicting effect of tumor immunotherapy using tumor cytotoxic activity of peripheral blood t cells as index
CA3067603A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
SG11202002089RA (en) 2017-09-08 2020-04-29 Maverick Therapeutics Inc Constrained conditionally activated binding proteins
US11643472B2 (en) 2017-10-12 2023-05-09 Mcmaster University T cell-antigen coupler with Y182T mutation and methods and uses thereof
JP2021502100A (en) 2017-11-08 2021-01-28 ゼンコア インコーポレイテッド Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN109879965B (en) * 2017-12-06 2022-11-11 北京科立思维生物科技有限公司 anti-EPHA 2 single-chain antibody, anti-CD 3E single-chain antibody, fusion protein and application thereof
JP2021506291A (en) 2017-12-19 2021-02-22 ゼンコア インコーポレイテッド Modified IL-2 FC fusion protein
JP2021508477A (en) 2017-12-29 2021-03-11 オンコラス， インコーポレイテッド Oncolytic virus delivery of therapeutic polypeptides
EP3773911A2 (en) 2018-04-04 2021-02-17 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
SG11202010163QA (en) 2018-04-18 2020-11-27 Xencor Inc Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
CN112437777A (en) 2018-04-18 2021-03-02 Xencor股份有限公司 TIM-3 targeting heterodimeric fusion proteins comprising an IL-15/IL-15RA Fc fusion protein and a TIM-3 antigen binding domain
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
US10640562B2 (en) 2018-07-17 2020-05-05 Mcmaster University T cell-antigen coupler with various construct optimizations
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
JP2022517989A (en) * 2019-01-14 2022-03-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Compositions and Methods for Modulating Cell Internal Translocation
WO2020160199A1 (en) * 2019-01-31 2020-08-06 Siemens Healthcare Diagnostics Inc. Anti-naloxone and anti-naltrexone monoclonal antibodies and methods of production and use thereof
BR112021016955A2 (en) 2019-03-01 2021-11-23 Xencor Inc Composition, nucleic acid composition, expression vector composition, expression vector, host cell, methods of producing an ectonucleotide pyrophosphatase/phosphodiesterase family 3 member binding domain and of treating a cancer, anti-enpp3 antibody , and, heterodimeric antibody
CN114390938A (en) 2019-03-05 2022-04-22 武田药品工业有限公司 Constrained conditionally activated binding proteins
JP7137696B2 (en) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド Methods and compositions for preventing type 1 diabetes
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
WO2022192403A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3
AU2022283819A1 (en) 2021-06-01 2024-01-04 Triumvira Immunologics Usa, Inc. Claudin 18.2 t cell-antigen couplers and uses thereof
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof
CN116970077A (en) * 2021-07-16 2023-10-31 西南医科大学 anti-EphA 2 fully human bivalent recombinant antibody scFv-Fc
WO2023010060A2 (en) 2021-07-27 2023-02-02 Novab, Inc. Engineered vlrb antibodies with immune effector functions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0826696B1 (en) * 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Use of bi-and trispecific antibodies for inducing tumor immunity
JP2006524693A (en) * 2003-04-11 2006-11-02 メディミューン，インコーポレーテッド EphA2 and non-neoplastic hyperproliferative cell disorders
RU2005137325A (en) * 2003-05-31 2006-09-10 Микромет Аг (De) PHARMACEUTICAL COMPOSITION CONTAINING A DESIGN SPECIFIC TO ERS
SI1629011T1 (en) * 2003-05-31 2010-05-31 Micromet Ag Human anti-human cd3 binding molecules
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
EP1673398B1 (en) * 2003-10-16 2010-12-29 Micromet AG Multispecific deimmunized cd3-binders

Also Published As

Publication number Publication date
WO2007073499A3 (en) 2008-10-02
AU2006327175A1 (en) 2007-06-28
KR20080090441A (en) 2008-10-08
JP2009521474A (en) 2009-06-04
WO2007073499A2 (en) 2007-06-28
RU2008129827A (en) 2010-01-27
EP1981532A4 (en) 2010-06-30
IL192279A0 (en) 2008-12-29
US20080044413A1 (en) 2008-02-21
CA2633713A1 (en) 2007-06-28
MX2008008046A (en) 2009-03-04
CN101426521A (en) 2009-05-06
EP1981532A2 (en) 2008-10-22

Similar Documents

Publication Publication Date Title
IL192279A0 (en) Epha2 bite molecules and uses thereof
ZA200810323B (en) Fkbp-l and uses thereof
IL228770A0 (en) Processes and intermaediates
SI2064327T1 (en) Dbait and uses thereof
GB0621160D0 (en) Compounds and uses thereof
GB0512940D0 (en) Compounds and their use
ZA200903906B (en) Carboranylporphyrins and uses thereof
ZA200804299B (en) 3-amino-2-arylpropyl azaindoles and uses thereof
IL189252A0 (en) Dihydroxyanthraquinones and their use
EP1912921A4 (en) Tetraazaporphyrin-based compounds and their uses
IL185223A0 (en) Compounds and uses thereof
EP2124908A4 (en) Compounds and uses thereof
GB0520743D0 (en) Compounds and their use
EP2164326A4 (en) Amide compounds and the use thereof
EP2120563A4 (en) Compounds and uses thereof
IL202496A0 (en) Compounds and uses thereof 849
EP1942911A4 (en) Therapeutic molecules and their uses
EP2099459A4 (en) Compounds and uses thereof
GB0610059D0 (en) Uses and methods
EP2120957A4 (en) Compounds and uses thereof
GB0521272D0 (en) Compounds and uses thereof
GB0514416D0 (en) Compounds and uses thereof
GB0515913D0 (en) Compounds and their uses
GB0514471D0 (en) Compounds and their uses
GB0506545D0 (en) Compounds and their uses